USA - NASDAQ:MLAB - US59064R1095 - Common Stock
The current stock price of MLAB is 73.14 USD. In the past month the price increased by 9.31%. In the past year, price decreased by -43.11%.
Symbol | Company Name | TA | FA | PE | Market Cap |
---|---|---|---|---|---|
TMO | THERMO FISHER SCIENTIFIC INC | 21.91 | 181.09B | ||
DHR | DANAHER CORP | 25.67 | 138.41B | ||
A | AGILENT TECHNOLOGIES INC | 23.18 | 35.81B | ||
IQV | IQVIA HOLDINGS INC | 16.32 | 31.83B | ||
MTD | METTLER-TOLEDO INTERNATIONAL | 30.94 | 26.07B | ||
WST | WEST PHARMACEUTICAL SERVICES | 36.62 | 18.33B | ||
WAT | WATERS CORP | 24.6 | 17.91B | ||
ILMN | ILLUMINA INC | 24.7 | 15.79B | ||
TEM | TEMPUS AI INC | N/A | 15.33B | ||
MEDP | MEDPACE HOLDINGS INC | 37.07 | 14.01B | ||
ICLR | ICON PLC | 13.15 | 13.53B | ||
RVTY | REVVITY INC | 17.73 | 10.07B |
Mesa Laboratories, Inc. engages in the design, manufacture, and market of instruments and disposable products utilized in healthcare, pharmaceutical, food and beverage, medical device, and petrochemical industries. The company is headquartered in Lakewood, Colorado and currently employs 730 full-time employees. The firm's segments include Sterilization and Disinfection Control, Clinical Genomics, Biopharmaceutical Development, and Calibration Solutions. Sterilization and Disinfection Control segment manufactures and sells biological, chemical and cleaning indicators. Clinical Genomics segment develops, manufactures and sells genetic analysis tools and related consumables and services. Biopharmaceutical Development segment develops, manufactures, sells and services automated systems for protein analysis and peptide synthesis solutions. Calibration Solutions segment develops, manufactures, sells and services control products using principles of advanced metrology to enable customers to measure and calibrate critical parameters in applications, such as renal care, environmental and process monitoring.
MESA LABORATORIES INC
12100 W 6th Ave
Lakewood COLORADO 80228 US
CEO: Gary M. Owens
Employees: 736
Phone: 13039878000
The current stock price of MLAB is 73.14 USD. The price increased by 5.74% in the last trading session.
The exchange symbol of MESA LABORATORIES INC is MLAB and it is listed on the Nasdaq exchange.
MLAB stock is listed on the Nasdaq exchange.
9 analysts have analysed MLAB and the average price target is 90.27 USD. This implies a price increase of 23.42% is expected in the next year compared to the current price of 73.14. Check the MESA LABORATORIES INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.
MESA LABORATORIES INC (MLAB) has a market capitalization of 402.27M USD. This makes MLAB a Small Cap stock.
MESA LABORATORIES INC (MLAB) currently has 736 employees.
MESA LABORATORIES INC (MLAB) has a resistance level at 73.15. Check the full technical report for a detailed analysis of MLAB support and resistance levels.
The Revenue of MESA LABORATORIES INC (MLAB) is expected to grow by 3.51% in the next year. Check the estimates tab for more information on the MLAB EPS, Sales, EBIT and EBITDA future analyst estimates.
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
MESA LABORATORIES INC (MLAB) has a dividend yield of 0.93%. The yearly dividend amount is currently 0.64. Check the full fundamental report for a detailed analysis of MLAB dividend history, reliability and sustainability.
MESA LABORATORIES INC (MLAB) will report earnings on 2025-11-05.
The PE ratio for MESA LABORATORIES INC (MLAB) is 914.25. This is based on the reported non-GAAP earnings per share of 0.08 and the current share price of 73.14 USD. Check the full fundamental report for a full analysis of the valuation metrics for MLAB.
The outstanding short interest for MESA LABORATORIES INC (MLAB) is 7.66% of its float. Check the ownership tab for more information on the MLAB short interest.
ChartMill assigns a technical rating of 1 / 10 to MLAB. When comparing the yearly performance of all stocks, MLAB is a bad performer in the overall market: 94.2% of all stocks are doing better.
ChartMill assigns a fundamental rating of 5 / 10 to MLAB. There are concerns on the financial health of MLAB while its profitability can be described as average.
Over the last trailing twelve months MLAB reported a non-GAAP Earnings per Share(EPS) of 0.08. The EPS decreased by -98.3% compared to the year before.
Industry Rank | Sector Rank | ||
---|---|---|---|
PM (TTM) | N/A | ||
ROA | -0.14% | ||
ROE | -0.36% | ||
Debt/Equity | 0.46 |
9 analysts have analysed MLAB and the average price target is 90.27 USD. This implies a price increase of 23.42% is expected in the next year compared to the current price of 73.14.
For the next year, analysts expect an EPS growth of 2600.57% and a revenue growth 3.51% for MLAB